Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Regulating MHC expression for cellular therapeutics.

Constança Figueiredo1, Peter A Horn, Rainer Blasczyk

  • 1Institute for Transfusion Medicine, Hanover Medical School, Hanover, Germany.

Transfusion
|January 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An international study on emerging arboviral infections and blood safety.

Transfusion·2026
Same author

Photon-counting CT for dynamic lung perfusion: validation of a low-dose protocol in a porcine lung transplantation model.

European radiology experimental·2026
Same author

Fundamentals of big data and artificial intelligence in transfusion medicine.

Vox sanguinis·2026
Same author

Developing and Assessing the Performance of a Machine Learning Model for Analyzing Drinking Behaviors in Minipigs for Experimental Research.

Sensors (Basel, Switzerland)·2026
Same author

A real-time dashboard for optimizing blood product utilization through a FHIR-based data integration pipeline.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same author

A Multimodal Pipeline for Clinical Data Extraction: Applying Vision-Language Models to Scans of Transfusion Reaction Reports.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same journal

Spray dried plasma manufactured from apheresis and whole blood derived plasma.

Transfusion·2026
Same journal

Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

Transfusion·2026
Same journal

AABB survey on directed blood donation practices.

Transfusion·2026
Same journal

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
Same journal

A novel translation initiation codon single nucleotide variant of the SLC14A1 (c.2T>G) from a Chinese blood donor with Jk(a-b-) phenotype.

Transfusion·2026
Same journal

Size (and frequency) matter: Evaluating the best management practices for blood products with spotty demand.

Transfusion·2026
See all related articles

Regenerative medicine faces immune rejection due to HLA polymorphism. This study uses lentivirus-delivered shRNAs to suppress HLA class I expression, overcoming immune barriers and advancing cell-based therapies.

Area of Science:

  • Regenerative medicine
  • Immunology
  • Gene therapy

Background:

  • Regenerative medicine aims to repair tissues but faces immune rejection challenges.
  • High human leukocyte antigen (HLA) polymorphism is a key barrier to immune acceptance in cell-based therapies.
  • Lentivirus-mediated delivery of short-hairpin RNAs (shRNAs) is an effective gene silencing method.

Purpose of the Study:

  • To investigate the feasibility of controlling HLA expression in cell-based therapeutics.
  • To overcome immune rejection limitations in regenerative medicine.

Main Methods:

  • Utilized a lentiviral vector system for drug-inducible expression of shRNA.
  • Targeted beta2-microglobulin (beta2m) or HLA heavy-chain transcripts for suppression.
  • Tested shRNA efficacy in HeLa, B-lymphocyte cell lines, and peripheral blood monocytes.

Related Experiment Videos

Main Results:

  • Suppressed HLA class I expression by up to 90% using shRNAs targeting beta2m or HLA heavy chain.
  • Demonstrated full restoration of HLA class I expression upon drug discontinuation.
  • Showed HLA class I knockdown prevents antibody-mediated cell lysis and CD8+ T-cell response.
  • Indicated residual HLA expression may protect against natural killer cell-mediated lysis.

Conclusions:

  • Genetically modifying cell-based therapeutics to control HLA expression is feasible.
  • This approach addresses immune rejection, a major hurdle for cellular therapies.
  • The findings bring advanced cellular therapies closer to clinical reality.